Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Markets Rise Midday as Inflation News Raises Expectations of a Rate Hike Pause
12:25pm, Tuesday, 13'th Jun 2023
U.S. equities gained at midday on Tuesday, June 13, 2023 as lower inflation raised optimism the Fed could pause its rate hike cycle.
European Alzheimer's experts unconvinced by new Eisai, Biogen drug
03:16am, Tuesday, 13'th Jun 2023
Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on sc
3-Stock Lunch: Oracle, Biogen and SentinelOne
03:25pm, Monday, 12'th Jun 2023
Eva Ados, ERShares chief operations officer, joins ‘Power Lunch' to discuss three stocks: Oracle, Biogen and SentinelOne.
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
10:47am, Monday, 12'th Jun 2023
Biogen (NASDAQ: BIIB ) stock is a hot topic among traders on Monday as the company's share resumed trading following a halt that was in effect on Friday. With that halt coming to an end, investors in
Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement
10:28am, Monday, 12'th Jun 2023
An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.
Biogen shares rise on imminent approval of Alzheimer's drug following FDA panel vote
08:46am, Monday, 12'th Jun 2023
Biogen Inc (NASDAQ:BIIB) shares rose in pre-market trading on Monday after a Food and Drug Administration (FDA) panel voted in favor of Eisai and Biogen's drug LEQEMBI as a treatment for Alzheimer's d
5 Things to Know Before Markets Open
07:35am, Monday, 12'th Jun 2023
UBS completes its takeover of Credit Suisse and Biogen wins key FDA support for its Alzheimer's disease treatment. Here's what investors need to know today.
Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns
06:26am, Monday, 12'th Jun 2023
Shares of Biogen Inc rose 4% in premarket trade on Monday as an unanimous backing of the company's Alzheimer's drug Leqembi by the U.S. regulator's advisers eased concerns that a traditional approval
Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move
05:38am, Monday, 12'th Jun 2023
Biogen Inc. shares BIIB, +1.31% rallied 5% following a full-day halt during the regular session as a Food and Drug Administration committee convened to vote on an approval recommendation for the biote
Biogen inches closer to FDA approval for its Alzheimer's drug
02:33pm, Saturday, 10'th Jun 2023
Shares of Biogen Inc (NASDAQ: BIIB) gained nearly 10% in extended hours after the biotech firm edged closer to winning FDA approval for its Alzheimer's drug. FDA panel greenlights Biogen's Leqembi Lat
Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer's drug for approval
07:27pm, Friday, 09'th Jun 2023
Biogen Inc. BIIB, +1.31% shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory c
Here's what the FDA's endorsement of the Alzheimer's drug Leqembi means for Biogen
05:33pm, Friday, 09'th Jun 2023
Matt Herper, Stat News senior writer, joins 'Closing Bell: Overtime' to discuss the FDA advisers' unanimous vote to recommend Biogen Alzheimer's drug.
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
02:29pm, Friday, 09'th Jun 2023
Biogen stock was halted Friday as a panel of experts to the FDA debated the merits of its Alzheimer's treatment, Leqembi.
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
10:07am, Friday, 09'th Jun 2023
Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.
FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen
07:04am, Friday, 09'th Jun 2023
A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for
